Back to top
more

Omeros (OMER)

(Real Time Quote from BATS)

$3.53 USD

3.53
67,569

-0.11 (-3.02%)

Updated May 8, 2024 01:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Analysts Estimate Omeros (OMER) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Omeros (OMER) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Omeros (OMER) delivered earnings and revenue surprises of 11.11% and -25.33%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Omeros (OMER) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Omeros (OMER) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Omeros (OMER) delivered earnings and revenue surprises of -2.50% and -23.88%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Omeros (OMER) Ahead of Earnings?

by Zacks Equity Research

Omeros (OMER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

InMode (INMD) to Post Q1 Earnings: What's in the Offing?

by Zacks Equity Research

InMode's (INMD) Q1 performance is likely to have been driven by developments in business segments amid coronavirus-led supply disruptions.

Company News for Mar 4, 2020

by Zacks Equity Research

Companies in the news are: SCON, OMER, QGEN, TLRY

Omeros (OMER) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Omeros (OMER) delivered earnings and revenue surprises of 36.36% and 6.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Omeros (OMER) delivered earnings and revenue surprises of 47.37% and 3.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Hold on to Chemed (CHE) Stock Right Now

by Zacks Equity Research

Investors continue to be optimistic about Chemed's (CHE) performance.

Omeros (OMER) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Omeros (OMER) delivered earnings and revenue surprises of 64.44% and 8.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Omeros (OMER) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Omeros (OMER) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Omeros (OMER) delivered earnings and revenue surprises of -11.76% and -4.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Omeros (OMER) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.

Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Omeros (OMER) delivered earnings and revenue surprises of 1.39% and 50.34%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Omeros (OMER) Q3 Earnings Expected to Decline

by Zacks Equity Research

Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Omeros (OMER) Surges: Stock Moves 10.2% Higher

by Zacks Equity Research

Omeros (OMER) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

    Omeros (OMER) Reports Q2 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Omeros (OMER) delivered earnings and revenue surprises of 9.09% and -5.75%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

      GW Pharma (GWPH) Q3 Earnings: Is a Turnaround in the Cards?

      by Zacks Equity Research

      GW Pharma (GWPH) is expected to report its fiscal third-quarter results next week. Investors focus is expected to be on the commercialization plan for Epidiolex.

        Benjamin Rains headshot

        These 3 Stocks Surged During Thursday's Sell-Off

        by Benjamin Rains

        Stocks saw rather large declines on Thursday, driven by concerns surrounding possible tariff-related retaliation from China against U.S. giants such as Boeing (BA), while Facebook's (FB) data breach woes escalated. These bellwethers helped contribute to a nearly 2.5% decline in the S&P 500 index as investors continue to assess the cost of rising interest rates and possible trade wars.

          Omeros Inks Agreement With FDA for OMS721 Phase III Trial

          by Zacks Equity Research

          Omeros (OMER) inks an agreement with the FDA on Omeros' protocol for a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy.

            Can Omeros (OMER) Run Higher on Strong Earnings Estimate Revisions?

            by Zacks Equity Research

            Omeros (OMER) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.

              Conatus' Liver Disease Drug Gets Orphan Drug Tag in the EU

              by Zacks Equity Research

              Conatus (CNAT) secures orphan drug designation for its pipeline candidate, IDN-7314, granted by the EMA. The candidate currently undergoes a phase II study on curing primary sclerosing cholangitis.

                Omeros (OMER) Hits New 52-Week High on Positive FDA Decision

                by Zacks Equity Research

                Omeros Corporation (OMER) shares hit a new 52-week high of $22.80 on Thursday before eventually closing at $22.15.